Identification of genomic alterations, e.g., TP53, LDL receptor-related protein 1B (LRP1B), HER2, and KRAS mutations, blood tumor mutation burden, and blood microsatellite instability status can provide recommendations for the clinical decision of advanced GC [98]. Here, ERBB2 is linked to neoplasm.